摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

α-p-Ethoxyanilino-benzylcyanid | 32323-75-4

中文名称
——
中文别名
——
英文名称
α-p-Ethoxyanilino-benzylcyanid
英文别名
p-phenetidino-phenyl-acetonitrile;α-p-Phenetidino-phenylessigsaeure-nitril;(α-Cyan-benzyl)-p-phenetidin;2-(4-Ethoxyanilino)-2-phenylacetonitrile
α-p-Ethoxyanilino-benzylcyanid化学式
CAS
32323-75-4
化学式
C16H16N2O
mdl
——
分子量
252.316
InChiKey
CUWGZVDGYWLPJU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.7
  • 重原子数:
    19
  • 可旋转键数:
    5
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.19
  • 拓扑面积:
    45
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    α-p-Ethoxyanilino-benzylcyanid盐酸 作用下, 以 乙醇 为溶剂, 反应 12.0h, 以88%的产率得到(4-Ethoxy-phenylamino)-phenyl-acetic acid; hydrochloride
    参考文献:
    名称:
    Naim, S. Shawkat; Khan, Naseem H.; Siddiqui, Amin A., Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1980, vol. 19, # 7, p. 622 - 624
    摘要:
    DOI:
  • 作为产物:
    描述:
    N-benzylidene-4-ethoxyaniline氰化钾溶剂黄146 作用下, 以 甲醇 为溶剂, 以93%的产率得到α-p-Ethoxyanilino-benzylcyanid
    参考文献:
    名称:
    Naim, S. Shawkat; Khan, Naseem H.; Siddiqui, Amin A., Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1980, vol. 19, # 7, p. 622 - 624
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • Cycloaddition Reactions of N-Sulphdvylanilines and N-(αCyano-α-aryl)-Methylanilines
    作者:Kewal Krishan Singal、Baldev Singh、Baldev Raj
    DOI:10.1080/00397919908086052
    日期:1999.3
    Abstract Through the cycloaddition of N-(α-cyano-α-aryl)-methylanilines (II) on to N-sulphinylanilines (III) are synthesized 2,3,5-triaryl-4-imino-2H, 3H, 5H-[1.2.5]thiadiazoIidin-l-oxides (TV) in aood vields.
    摘要 通过 N-(α-基-α-芳基)-甲基苯胺 (II) 与 N-亚磺基苯胺 (III) 的环加成反应合成了 2,3,5-三芳基-4-亚基-2H, 3H, 5H-[ 1.2.5]aood 领域中的 thiadiazolidin-l-oxides (TV)。
  • LAPAROSCOPIC NEPHROURETERECTOMY FOR UPPER TRACT TRANSITIONAL CELL CANCER: THE WASHINGTON UNIVERSITY EXPERIENCE
    作者:ARIEH L. SHALHAV、MATTHEW D. DUNN、ANDREW J. PORTIS、ABDELHAMID M. ELBAHNASY、ELSPETH M. M c DOUGALL、RALPH V. CLAYMAN
    DOI:10.1016/s0022-5347(05)67701-4
    日期:2000.4
    Purpose: Laparoscopic nephroureterectomy has only recently been done to treat patients with upper tract transitional cell carcinoma. We retrospectively evaluated our experience with and long-term followup of laparoscopic nephroureterectomy, compared our results to those of contemporary series of open nephroureterectomy and reviewed the literature.Materials and Methods: We reviewed the charts of and followed up by telephone 25 patients who underwent laparoscopic nephroureterectomy between May 1991 and June 1998, and 17 who underwent open nephroureterectomy between March 1990 and January 1997. Demographic, perioperative and followup data were compared. We performed a MEDLINE search and reviewed the literature on laparoscopic nephroureterectomy for upper tract transitional cell carcinoma.Results: Laparoscopic nephroureterectomy required twice the operating time of open nephroureterectomy (7.7 versus 3.9 hours). However, patients who underwent the laparoscopic procedure had a 74% decrease in analgesia requirements (37 versus 144 mg. morphine sulfate equivalent), a 63% shorter hospital stay (3.6 versus 9.6 days) and a 72% more rapid convalescence (2.8 versus 10 weeks). Subsequent bladder transitional cell carcinoma and overall cancer specific survival were similar at a mean followup of 2 years. There was no sign of trocar site or peritoneal seeding after laparoscopic nephroureterectomy.Conclusions: Although laparoscopic nephroureterectomy is a longer operation, it has the same efficacy and is better tolerated by patients than open nephroureterectomy for upper tract transitional cell carcinoma. As operating time decreases due to surgeon experience and the recent development of hand assisted laparoscopy, laparoscopic nephroureterectomy may soon become the procedure of choice for the ablative management of upper tract transitional cell carcinoma.
查看更多

同类化合物

(R)-3-(叔丁基)-4-(2,6-二异丙氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (2S,3R)-3-(叔丁基)-2-(二叔丁基膦基)-4-甲氧基-2,3-二氢苯并[d][1,3]氧杂磷杂戊环 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-二甲氧基-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2R,2''R,3R,3''R)-3,3''-二叔丁基-4,4''-二甲氧基-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2-氟-3-异丙氧基苯基)三氟硼酸钾 (+)-6,6'-{[(1R,3R)-1,3-二甲基-1,3基]双(氧)}双[4,8-双(叔丁基)-2,10-二甲氧基-丙二醇 麦角甾烷-6-酮,2,3,22,23-四羟基-,(2a,3a,5a,22S,23S)- 鲁前列醇 顺式6-(对甲氧基苯基)-5-己烯酸 顺式-铂戊脒碘化物 顺式-四氢-2-苯氧基-N,N,N-三甲基-2H-吡喃-3-铵碘化物 顺式-4-甲氧基苯基1-丙烯基醚 顺式-2,4,5-三甲氧基-1-丙烯基苯 顺式-1,3-二甲基-4-苯基-2-氮杂环丁酮 非那西丁杂质7 非那西丁杂质3 非那西丁杂质22 非那西丁杂质18 非那卡因 非布司他杂质37 非布司他杂质30 非布丙醇 雷诺嗪 阿达洛尔 阿达洛尔 阿莫噁酮 阿莫兰特 阿维西利 阿索卡诺 阿米维林 阿立酮 阿曲汀中间体3 阿普洛尔 阿普斯特杂质67 阿普斯特中间体 阿普斯特中间体 阿托西汀EP杂质A 阿托莫西汀杂质24 阿托莫西汀杂质10 阿托莫西汀EP杂质C 阿尼扎芬 阿利克仑中间体3 间苯胺氢氟乙酰氯 间苯二酚二缩水甘油醚 间苯二酚二异丙醇醚 间苯二酚二(2-羟乙基)醚 间苄氧基苯乙醇 间甲苯氧基乙酸肼 间甲苯氧基乙腈 间甲苯异氰酸酯